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Yield of Opportunistic Targeted Screening 
for Type 2 Diabetes in Primary Care: 
The Diabscreen Study
ABSTRACT
PURPOSE In screening for type 2 diabetes, guidelines recommend targeting 
high-risk individuals. Our objectives were to assess the yield of opportunistic tar-
geted screening for type 2 diabetes in primary care and to assess the diagnostic 
value of various risk factors.
METHODS In 11 family practices (total practice population = 49,229) in The 
Netherlands, we conducted a stepwise opportunistic screening program among 
patients aged 45 to 75 years by (1) identifying high-risk individuals (≥1 diabetes 
risk factor) and low-risk individuals using the electronic medical record, (2) obtain-
ing a capillary fasting plasma glucose measurement, repeated on a separate day 
if the value was greater than 110 mg/dL, and (3) obtaining a venous sample if 
both capillary fasting plasma glucose values were greater than 110 mg/dL and 
at least 1 sample was 126 mg/dL or greater. We calculated the yield (percentage 
of invited patients with undiagnosed diabetes), number needed to screen (NNS), 
and diagnostic value of the risk factors (odds ratio and area under the receiver 
operating characteristic curve).
RESULTS We invited for a fi rst capillary measurement 3,724 high-risk patients 
seen during usual care and a random sample of 465 low-risk patients contacted 
by mail. The response rate was 90% and 86%, respectively. Ultimately, 101 
high-risk patients (2.7%; 95% confi dence interval [CI], 2.2%-3.3%; NNS = 37) 
and 2 low-risk patients (0.4%; 95% CI, 0.1%-1.6%; NNS = 233) had undiagnosed 
diabetes (P <.01). The prevalence of diabetes among patients 45 to 75 years old 
increased from 6.1% to 6.8% as a result. Among diagnostic models containing 
various risk factors, a model containing obesity alone was the best predictor 
of undiagnosed diabetes (odds ratio = 3.2; 95% CI, 2.0-5.2; area under the 
curve = 0.63).
CONCLUSIONS The yield of opportunistic targeted screening was fair; obesity 
alone was the best predictor of undiagnosed diabetes. Opportunistic screening 
for type 2 diabetes in primary care could target middle-aged and older adults 
with obesity.
Ann Fam Med 2009;7:422-430. doi:10.1370/afm.997.
INTRODUCTION
Primary care clinicians are encouraged to be more proactive in detecting and treating both diabetes and prediabetes.1 The recently updated standards of medical care of the American Diabetes Asso-
ciation (ADA) recommend testing adults of any age who are overweight or 
obese and have additional diabetes risk factors.2
The main reason to recommend screening for type 2 diabetes is the 
disease’s long preclinical period of up to 12 years. The condition goes 
undiagnosed in one-third to one-half of all people with type 2 diabetes 
during this entire period, and they already have complications by the time 
of diagnosis.3
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Starting treatment at an earlier stage might prevent 
or delay the development of diabetes complications. 
Studies have shown that in clinically detected (not 
screening-detected) diabetes, tight glycemic control 
can reduce the progression of microvascular disease, 
and that treatment of hypertension and hyperlipidemia 
decreases cardiovascular risk.4 Screening for and treat-
ing prediabetes—impaired fasting glucose (IFG) and 
impaired glucose tolerance—might prevent or slow the 
progression to diabetes and reduces the risk of cardio-
vascular disease.1,5
At present, however, randomized controlled trials 
have failed to show that earlier detection by screening 
reduces morbidity, mortality, or both among people 
with undiagnosed type 2 diabetes.4,6 There is also little 
knowledge about the ethical, psychological, and social 
consequences of screening results that are truly or 
falsely positive or negative, and there is no consensus 
on which screening tests to use and which diagnostic 
cutoff points are best.7-9
These considerations notwithstanding, screening 
for diabetes is encouraged nowadays. Targeting high-
risk patients is recommended, as there is no evidence 
of a direct beneﬁ t of routine population-based screen-
ing for type 2 diabetes.2,4,10-12 As screening should also 
be a systematic and continuous process,7 opportunis-
tic targeted screening might be a valuable screening 
method in primary care. This method entails screening 
high-risk individuals during usual care.6
The pragmatic nature of opportunistic targeted 
screening enables initiation of further diagnostic 
testing and treatment of newly diagnosed type 2 dia-
betes. To investigate this approach, we performed a 
study of a stepwise opportunistic screening program 
embedded in daily routine care in family practices in 
The Netherlands, targeting high-risk patients—the 
Diabscreen study. In the analysis reported here, our 
objectives were to assess the yield of our screening 
program and the diagnostic value of the risk factors 
we used in the study.
METHODS
Participants and Setting
Participants were recruited from 11 family practices in 
The Netherlands that were part of academic research 
networks of university departments of family medicine. 
The practices had a total population of 49,229 patients, 
cared for by 25 family practitioners, and had not pre-
viously performed systematic screening for diabetes. 
Seven of the practices were from the Radboud Univer-
sity Nijmegen Medical Centre,13 2 were from Maas-
tricht University,14 and 2 were from the Amsterdam 
VU University Medical Centre.15 We considered for 
inclusion in the study all patients aged 45 to 75 years 
inclusive who were listed with these practices and were 
not known to have diabetes. In The Netherlands, every 
individual in the population is registered with a fam-
ily practitioner, usually the same one for many years. 
Patients need a referral by a family practitioner to con-
sult a specialist.
All practices used an electronic medical record 
(EMR) with the same software (Promedico ICT Inc, 
Nieuwegein, The Netherlands) containing relevant 
medical information, such as medical history, diagno-
ses, medication use, and referrals. Coding of diagnoses 
was based on the electronic version of the International 
Classiﬁ cation of Primary Care (ICPC) codes.16 Prescribed 
medication was coded according to Anatomical Thera-
peutic Chemical (ATC) codes.17
In our study, patients were deﬁ ned as having undi-
agnosed type 2 diabetes if they had a venous fasting 
plasma glucose (FPG) value of at least 126 mg/dL.* 
They were deﬁ ned as having IFG if they had a venous 
FPG value of greater than 110 mg/dL and less than 
126 mg/dL.18,19 We did not study impaired glucose 
tolerance, because our pragmatic screening protocol 
involved only FPG testing and not an oral glucose 
challenge.
Ethical approval for the study was obtained from 
the Radboud University Nijmegen Medical Centre 
ethics committee.
Screening Program
Our opportunistic screening program consisted of a 
stepwise screening procedure: (1) using the EMR, iden-
tiﬁ cation of high-risk and low-risk individuals; (2) a ﬁ rst 
capillary FPG measurement and, if indicated by the 
result, a second one; and (3) if indicated by that result, 
a venous FPG.
We considered patients to be at high risk for undi-
agnosed type 2 diabetes if they had 1 or more of the 
following diabetes risk factors, derived from the ADA 
recommendations for screening for type 2 diabetes2: a 
family history of diabetes (deﬁ ned as diabetes in a par-
ent, brother, or sister, or some combination thereof), 
hypertension, cardiovascular disease (myocardial 
infarction, heart failure, atrial ﬁ brillation, stroke, 
peripheral vascular disease), lipid metabolism disorders, 
obesity (body mass index >27 kg/m2), and a history of 
gestational diabetes mellitus.2,11
We translated these risk factors into a set of match-
ing ICPC and ATC codes.20 Using a computerized 
cross-sectional analysis of ICPC and ATC informa-
tion for each patient from the practices’ EMR, we 
determined the patients’ diabetes risk status (high vs 
* Conversion factor to SI units is × 0.0555. 
ANNALS OF FAMILY MEDICINE ✦ WWW.ANNFAMMED.ORG ✦ VOL. 7, NO. 5 ✦ SEPTEMBER/OCTOBER 2009
424
OPPORTUNIST IC SCREENING FOR T YPE 2 DIABETES
low) and entered it in the EMR. During a usual care 
consultation in the following year, the EMR reminded 
the family practitioners to verify and, in the case of 
missing data, complete the patients’ risk proﬁ le and to 
invite high-risk patients for an FPG measurement. As 
part of daily practice, an appointment for this test was 
recorded in the practice schedule. There were no fur-
ther reminders.
In addition, to assess the yield of opportunistic 
screening among low-risk patients, from each partici-
pating practice, we also invited for FPG measurement 
a random sample of low-risk patients: patients from the 
same age-group, but without any of the risk factors 
listed above. On the basis of an expected prevalence 
of undiagnosed type 2 diabetes of 0.5%,21 an intraclass 
correlation coefﬁ cient of 0.03, and a desired precision 
of 1%, we calculated a required sample size of 380 low-
risk patients. These patients were randomly selected 
from a list of low-risk patients and subsequently invited 
by mail to visit the practice for screening.
Our stepwise screening protocol was based on cut-
off points used for IFG and diabetes.22 All patients with 
an initial capillary FPG of greater than 110 mg/dL were 
invited for a second capillary measurement on another 
day. This second measurement was immediately fol-
lowed by a venous FPG measurement if both capillary 
measurements were greater than 110 mg/dL and at least 
1 was 126 mg/dL or greater.
Measurements
Measurements were made in the patients’ own family 
practice by the regular practice assistants. Capillary 
samples were taken using a Gluco Touch plasma-cali-
brated capillary blood glucose meter (LifeScan Ben-
elux, Beerse, Belgium). Before the start of the study, 
all participating practices received new meters, which 
were checked and adjusted, if necessary, by the manu-
facturer. The practice assistants were trained in using 
the meters. Venous samples were sent to a central labo-
ratory for further analysis in a Roche/Hitachi chemical 
analyzer (Roche Nederland BV, Woerden, The Nether-
lands), using the glucose oxidase method.
Data Analysis
We analyzed data with SPSS 16.0 for Windows (SPSS 
Inc, Chicago, Illinois). Statistical analysis was performed 
using the χ2 test for categorical data and the Student 
t test or Kruskal-Wallis test for means where appropri-
ate. We considered a P value <.05 to be signiﬁ cant.
We calculated the yield of our screening program 
(the percentage of invited patients found to have undi-
agnosed type 2 diabetes); the number of patients who 
would need to be invited for screening in order to 
identify 1 patient with undiagnosed type 2 diabetes, 
or number needed to screen (NNS); and the change in 
diabetes prevalence among the study population result-
ing from the program.
We examined possible interactions between the 
risk factors by calculating the correlation coefﬁ cients. 
Then, we quantiﬁ ed their association with the presence 
or absence of undiagnosed diabetes using univariate 
logistic regression analysis. Variables with a P value 
≤.15 were included in multivariate binary logistic 
regression analysis to determine their independent 
contribution to the risk of undiagnosed type 2 dia-
betes. Using the backward stepwise (likelihood ratio) 
method, excluding variables one by one, we were able 
to produce diagnostic models with an area under the 
receiver operating characteristic curve (AUC).
RESULTS
The 11 participating practices had 49,229 registered 
patients (2,500-9,750 per practice), of whom 14,457 
(957-1,831 per practice) were aged 45 to 75 years (Fig-
ure 1). The prevalence of known diabetes before our 
screening program was 6.1%, leaving 13,581 patients 
for the study. During the 1-year study period, 5,277 
(39%) of these patients had an encounter with a fam-
ily practitioner during which screening was discussed. 
Risk assessment indicated that 3,724 (71%) were at 
high risk for diabetes and 1,553 (29%) were at low 
risk; 90% of the high-risk patients and 86% of the 465 
invited low-risk patients returned for a ﬁ rst capillary 
FPG measurement after invitation. Sex and mean age 
did not differ signiﬁ cantly between high-risk and low-
risk patients, but mean FPG was slightly higher in the 
former group (Table 1).
High-Risk Patients
A second capillary FPG was performed in 496 high-risk 
patients, or 88% of those invited (Figure 1). According 
to our protocol, 169 (5%) were eligible for venous FPG 
measurement immediately after the second capillary 
FPG measurement. A venous sample was collected in 
125 (74%) of these patients but not in 44 (26%). In the 
latter group, the second capillary FPG more often was 
110 to 126 mg/dL, but other characteristics did not dif-
fer signiﬁ cantly between groups (Table 2). Of the 125 
patients with a venous sample, 81% had undiagnosed 
type 2 diabetes, 16% had IFG, and 3% had a normal 
fasting glucose level. These groups differed signiﬁ -
cantly in terms of mean FPG values and the prevalence 
of lipid metabolism disorders (Table 3).
Low-Risk Patients
In the low-risk group, only 2 patients had undiagnosed 
type 2 diabetes and 1 patient had IFG (Figure 1). The 
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Figure 1. Study population and algorithm of the screening procedure. 
cFPG1 = fi rst capillary fasting plasma glucose; cFPG2 = second capillary fasting plasma glucose; vFPG = venous fasting plasma glucose; NFG = normal fasting plasma 
glucose; IFG = impaired fasting glucose.
a Conversion factor to SI units: x 0.0555.
Population 11 practices
n =49,229
Population 45-75 years
n =14,457
Known diabetes mellitus
n = 876 (6.1%)
No known diabetes mellitus
n = 13,581
During the study period of 1 year, no 
consultation or screening not discussed
n = 8,304 (61%)
During study, consultation and screening discussed
n = 5,277 (39%)
High risk, invited during 
consultation for cFPG1
n = 3,724 (71%)
Low risk, not invited 
for cFPG1
n = 1,088 (20%)
Low risk, invited by 
mail for cFPG1
n = 465 (9%)
Did not return for cFPG1
n = 389 (10%)
Did not return for cFPG1
n = 67 (14%)
cFPG1 measured
n = 3,335 (90%)
cFPG1 measured
n = 398 (86%)
cFPG1 >110 mg/dLa
n = 566 (17%)
cFPG1 >110 mg/dLa
n = 22 (5.5%)
cFPG2 measured
n = 496 (88%)
cFPG2 measured
n = 19 (86%)
cFPG1 >110 mg/dLa and cFPG1 or 2 ≥126 mg/dLa
n = 169 (34%)
cFPG1 >110 mg/dLa and cFPG1 or 2 ≥126 mg/dLa
n = 3 (16%)
vFPG measured
n = 125 (74%)
vFPG measured
n = 3 (100%)
NFG
n = 4 (3%)
IFG
n = 20 (16%)
Type 2 diabetes
n = 101 (81%)
Type 2 diabetes
n = 2 (67%)
IFG
n = 1 (33%)
NFG
n = 0 (0%)
ANNALS OF FAMILY MEDICINE ✦ WWW.ANNFAMMED.ORG ✦ VOL. 7, NO. 5 ✦ SEPTEMBER/OCTOBER 2009
426
OPPORTUNIST IC SCREENING FOR T YPE 2 DIABETES
characteristics within each subgroup are displayed in 
Table 3. Further analysis was not possible in this group 
because of the small number of patients.
Yield of the Screening Program
We found undiagnosed type 2 diabetes in 101 high-
risk patients and 2 low-risk patients. These values 
corresponded to 2.7% of high-risk 
patients (95% conﬁ dence interval 
[CI], 2.2%-3.3%; NNS = 37) vs 
0.4% of low-risk patients (95% CI, 
0.1%-1.6%; NNS = 233) invited for 
screening (P <.01). As a result of the 
screening program, the prevalence 
of known diabetes among patients 
aged 45 to 75 years in the study 
practices increased from 6.1% (876 
patients) to 6.8% (979 patients).
Diagnostic Value 
of the Risk Factors
There were signiﬁ cant but no rel-
evant correlations between the risk 
factors. For example, the Spear-
man rank correlation coefﬁ cient of 
obesity with hypertension was 0.08 
with P <.01 (data not further shown).
Univariate logistic regression 
analysis showed that the odds 
of undiagnosed type 2 diabetes 
were signiﬁ cantly higher among 
patients who were obese (odds ratio 
[OR] = 3.2; 95% CI, 2.0-5.2) or had 
Table 1. Baseline Characteristics of High-Risk and Low-Risk 
Patients in Whom a First Capillary Fasting Plasma Glucose Level 
Was Measured
Characteristic
High-Risk 
Patients
(n = 3,335)
Low-Risk 
Patients
(n = 398) P Value
Sex (male), No. (%) 1,411 (42.3) 168 (42.2) .97
Age, mean (SD), years 58.2 (8.2) 57.5 (7.2) .07
cFPG1
cFPG1, mean (SD), mg/dLa 99.1 (21.6) 93.7 (10.8) <.001
cFPG1 110-126 mg/dL, No. (%) 394 (11.8) 16 (4.0) <.001
cFPG1 ≥126 mg/dL, No. (%) 172 (5.2) 6 (1.5) <.001
BMIb
BMI, mean (SD), kg/m2 28.0 (4.5) 23.5 (2.2) <.001
BMI >27 kg/m2, No. (%) 1,786 (57.4) 0 –
Risk factors
Hypertension, No. (%) 814 (24.4) 0 –
Cardiovascular disease, No. (%) 499 (15.0) 0 –
Lipid metabolism disorders,c No. (%) 319 (32.1) 0 –
Family history of diabetes, No. (%) 1,288 (38.6) 0 –
History of GDM,d No. (%) 17 (2.8) 0 –
BMI = body mass index; cFPG1 = fi rst capillary fasting plasma glucose; GDM = gestational diabetes mellitus.
a Conversion factor to SI units: × 0.0555.
b Missing = 225.
c  Missing = 2,342. 
d Missing = 2,726.
Table 2. Characteristics of High-Risk Patients Eligible For Venous FPG Measurement, 
Comparing Patients With and Without a Venous Sample
Characteristic
Patients With 
Venous Sample
(n = 125)
Patients Without 
Venous Sample
(n = 44) P Value
Sex (male), No. (%) 57 (45.6) 23 (52.3) .45
Age, mean (SD), years 58.8 (8.0) 58.5 (8.1) .87
cFPG measurements
cFPG1, mean (SD), mg/dLa 156.8 (55.9) 151.4 (50.5) .59
cFPG2, mean (SD), mg/dL 149.5 (41.4) 140.5 (37.8) .23
cFPG1 110-126 mg/dL and cFPG2 ≥126 mg/dL, No. (%) 28 (22.4) 6 (13.6) .21
cFPG1 ≥126 mg/dL and cFPG2 110-126 mg/dL, No. (%) 22 (17.6) 21 (47.8) <.001
cFPG1 ≥126 mg/dL and cFPG2 ≥126 mg/dL, No. (%) 75 (60.0) 17 (38.6) .01
BMI, mean (SD), kg/m2 30.2 (4.6) 31.0 (6.9) .39
Risk factors
Hypertension, No. (%) 49 (39.2) 15 (34.1) .55
Cardiovascular disease, No. (%) 22 (17.6) 5 (11.4) .33
Lipid metabolism disorders,b No. (%) 12 (38.7) 3 (21.4) .41
Family history of diabetes, No. (%) 58 (46.4) 17 (38.6) .37
History of GDM,c No. (%) 0 0 –
BMI = body mass index; FPG = fasting plasma glucose; cFPG1 = fi rst capillary fasting plasma glucose; cFPG2 = second capillary fasting plasma glucose; GDM = gesta-
tional diabetes mellitus.
a Conversion factor to SI units: × 0.0555.
b Missing = 94 with venous sample; 30 without venous sample.
c Missing = 100 with venous sample; 26 without venous sample.
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hypertension (OR = 2.5; 95% CI, 1.6-3.8) (Table 4). 
In contrast, a family history of diabetes was not sig-
niﬁ cantly associated with undiagnosed diabetes (OR = 
1.4; 95% CI, 0.9-2.1). Because of the large number of 
missing data, lipid metabolism disorders and history of 
gestational diabetes mellitus were not included in the 
analysis.
Multivariate binary logistic regression analysis 
showed that obesity was the best predictor of undiag-
nosed type 2 diabetes: 76.8% of those with the disease 
were obese (AUC = 0.63; 95% conﬁ dence interval, 
0.58-0.68) (Table 5). Hypertension and family history 
of diabetes were poorer predictors.
DISCUSSION
The yield of our opportunistic targeted screening 
program was fair: in 1 year we identiﬁ ed undiagnosed 
type 2 diabetes in 101 high-risk patients invited for 
screening (2.7%, NNS = 37). This number represents 
30% of cases of known diabe-
tes, considering that 39% of the 
study population had an encoun-
ter with a family practitioner 
(39% of 876 patients previously 
known to have diabetes = 342, 
and 101/342 = 30%). The yield of 
screening in low-risk patients was, 
as expected, only 0.4% (NNS = 
233). The response rate for the 
capillary measurements was high, 
at about 90%. As a result of the 
screening program, the preva-
lence of known diabetes among 
our patients aged 45 to 75 years 
Table 4. Univariate Analysis of the Association Between Diabetes 
Risk Factors and the Odds of Undiagnosed Type 2 Diabetes 
Risk Factor
Undiagnosed Diabetes
Odds Ratio 
(95% CI) P Value
Yes, No. (%)
(n = 95) 
No, No. (%)
(n = 3,379)
Sex (male) 46 (48.4) 1,431 (42.3) 1.3 (0.9-1.9) .24
Age >60 years 45 (47.4) 1,406 (41.6) 1.3 (0.8-1.9) .26
Hypertension 37 (38.9) 691 (20.4) 2.5 (1.6-3.8) <.001
Cardiovascular disease 16 (16.8) 429 (12.7) 1.4 (0.8-2.4) .23
Obesity (BMI >27 kg/m2) 73 (76.8) 1,713 (50.7) 3.2 (2.0-5.2) <.001
Family history of diabetes 41 (43.2) 1,212 (35.9) 1.4 (0.9-2.1) .15
BMI = body mass index; CI = confi dence interval.
Note: Missing = 259.
Table 3. Characteristics of High-Risk and Low-Risk Patients in Venous FPG Subgroups
Characteristic
High-Risk Patients Low-Risk Patients
Diabetes
(n = 101)
IFG
(n = 20)
NFG
(n = 4)
Diabetes
(n = 2)
IFG
(n = 1)
NFG
(n = 0)
Sex (male), No. (%) 49 (48.5) 6 (30.0) 2 (50.0) 1 (50.0) 0 0
Age, mean (SD), years 59.4 (8.1) 56.0 (7.8) 55.8 (2.6) 67.5 (6.4) 55.0 0
Plasma glucose levela
cFPG1, mean (SD), mg/dL 162.2 (59.5) 129.7 (12.6) 126.0 (7.2)b 127.9 (1.8) 127.9 0
cFPG2, mean (SD), mg/dL 155.0 (43.2) 124.3 (14.4) 117.1 (7.2)c 135.1 (3.6) 129.7 0
vFPG, mean (SD), mg/dL 164.0 (41.4) 120.7 (3.6) 104.5 (5.4)d 133.3 (7.2) 110.0 0
BMIe
BMI, mean (SD), kg/m2 29.9 (3.9) 32.2 (6.9) 28.2 (4.8) 25.3 (1.5) 25.3 0
BMI >27 kg/m2, No. (%) 73 (78.5) 17 (89.5) 2 (50.0) 0 0 0
Risk factors
Hypertension, No. (%) 41 (40.6) 7 (35.0) 1 (25.0) 0 0 0
Cardiovascular disease, No. (%) 17 (16.8) 5 (25.0) 0 0 0 0
Lipid metabolism disorders,f No. (%) 6 (23.1) 6 (66.7) 0b 0 0 0
Family history of diabetes, No. (%) 43 (42.6) 13 (65.0) 2 (50.0) 0 0 0
History of GDM,g No. (%) 0 0 0 0 0 0
BMI = body mass index; cFPG1 = fi rst capillary fasting plasma glucose; cFPG2 = second capillary fasting plasma glucose; FPG = fasting plasma glucose; vFPG = venous 
fasting plasma glucose; GDM = gestational diabetes mellitus; IFG = impaired fasting glucose; NFG = normal fasting glucose.
Note: Statistical analysis of the low-risk group was not possible because of the small numbers. 
a Conversion factor to SI units: × 0.0555.
b P <.05 in high-risk group. 
c P <.01 in high-risk group. 
d P <.001 in high-risk group. 
e Missing in high-risk group = 8 with diabetes; 1 with IFG; 0 with NFG.
f Missing in high-risk group = 75 with diabetes; 11 with IFG; 3 with NFG.
g Missing in high-risk group = 80 with diabetes; 17 with IFG; 3 with NFG.
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increased from 6.1% to 6.8%. Of the ADA diabetes 
risk factors, obesity was the best predictor of undiag-
nosed type 2 diabetes.
The main strength of the study was the setting. 
High-risk patients were invited for screening during 
daily routine practice in the patients’ local family prac-
tice by their own family practitioner. Capillary blood 
samples were taken by the practice assistants, without 
any further support (eg, from trial nurses). Although 
patients had to return in a fasting state for the capil-
lary FPG measurements, they were highly willing to 
do so. And although all participating family practices 
were related to a university department of family medi-
cine, they were standard community practices with 
a population representative of the Dutch population 
and a diabetes prevalence equal to that in The Neth-
erlands.13-15,23 Because the Dutch system of primary 
health care provides for universal access and continuity 
of patient registration, we were able to use the family 
practice EMR in a continuous screening program.
Our screening approach calls for the identiﬁ cation 
of individual risk factors during a regular consultation. 
To the extent possible, we used available information 
from the EMR, which is based on the ICPC. A limit-
ing factor is that not all risk factors are included in the 
ICPC at this time; therefore, we had to ask patients 
about their risk factors to conﬁ rm their status.20 Our 
study supports the relevance of routine inclusion of 
risk factors in the EMR and the importance of expand-
ing the ICPC to include this information.
A possible limitation was that we used the FPG test 
rather than the oral glucose tolerance test. The latter 
test consists of an FPG measure-
ment plus a 2-hour plasma glu-
cose measurement, and has been 
considered to be the criterion 
standard in diagnosing diabetes. 
The FPG test is, nevertheless, 
recommended for screening in 
primary care as it is easier and 
faster to perform, more conve-
nient and acceptable to patients, 
and less expensive.2,24
Our focus was on testing 
the applicability of our stepwise 
protocol during usual care; 
therefore, we did not collect 3 
blood samples (2 capillary and 
1 venous) from all study par-
ticipants. With an 81% concor-
dance between identiﬁ cation for 
venous sampling and an undiag-
nosed type 2 diabetes outcome 
in high-risk patients (positive 
predictive value = 81%), our protocol was very useful. 
Since this protocol was designed to screen for undi-
agnosed type 2 diabetes, few patients who underwent 
venous sampling were found to have IFG.
In 26% of our high-risk patients eligible for a 
venous sample, this measurement was not performed. 
Considering the high level of compliance with the cap-
illary measurements, the general lack of signiﬁ cant dif-
ferences between patients with a venous measurement 
and those without, and the requirement by the proto-
col that the venous sample be obtained immediately 
after the second capillary measurement, we believe 
that the missing venous samples were mainly due to 
protocol factors (eg, misinterpretation—willingly or 
not—by the practice assistants) instead of patient fac-
tors. The fact that high-risk patients without a venous 
sample more often had a second capillary FPG of 110 
to 126 mg/dL supports this assumption. Instead of giv-
ing assistants a ﬂ owchart with all possible combinations 
of glucose outcomes (not described) as we did in the 
study, we now believe it would have been more helpful 
if we had given them the simple algorithm mentioned 
in the “Methods” section. We estimate that if compli-
ance had been 100%, the number of newly diagnosed 
cases of diabetes among high-risk patients could in fact 
have been 136, giving an even lower NNS of 28.
The portable glucose meters we used are user-
friendly and readily available in primary care. A poten-
tial drawback is their variability,25 and consequent risk 
of false-positive and false-negative outcomes. Our 
stepwise approach, in which patients with glucose lev-
els above the threshold underwent measurement again, 
Table 5. Multivariate Analysis of the Association Between Diabetes 
Risk Factors and the Odds of Undiagnosed Type 2 Diabetes and 
Diagnostic Performance
Model
Odds Ratio 
(95% CI)
P 
Value
Undiagnosed 
Diabetes, 
No. (%)
(n = 95) AUC (95% CI)a
Model 1 12 (12.6) 0.54 (0.48-0.61)
Obesity (BMI >27 kg/m2) 3.1 (1.9-5.0) <.001 – –
Hypertension 2.3 (1.5-3.5) <.001 – –
Family history of diabetes 1.4 (1.0-2.2) .09 – –
Model 2 30 (31.6) 0.60 (0.54-0.66)
Obesity 3.0 (1.9-4.9) <.001 – –
Hypertension 2.3 (1.5-3.5) <.001 – –
Model 3 73 (76.8) 0.63 (0.58-0.68)
Obesity 3.2 (2.0-5.2) <.001 – –
AUC = area under the receiver operating characteristic curve; BMI = body mass index; CI = confi dence interval.
Note: Only risk factors with P ≤.15 in Table 4 were included.
a An AUC of 0.50 means that the model does not predict the outcome better (more accurately) or worse (less 
accurately) than random guess; an AUC greater than 0.50 means that the prediction is better than random, and 
an AUC less than 0.50 means that the prediction is worse than random.
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did address the problems of false-positive results.22 To 
address false-negative results, the procedure must be 
repeated, for example, every 3 years, as recommended 
by the ADA.2
Since we wanted to perform a screening program 
embedded in daily care without any further support, 
we did not speciﬁ cally study disadvantages or harms, 
or cost-effectiveness of our opportunistic screening 
program, nor did we speciﬁ cally investigate acceptabil-
ity of the screening procedure. As the program was 
embedded in daily care and the patient attendance 
rate was 90%, however, we believe we can conclude 
that it was inexpensive and feasible. Further research is 
needed, though.
Several diabetes screening studies have been 
described in the literature. Smith et al26 undertook 
an opportunistic diabetes screening study performed 
in family practice using a questionnaire presented to 
patients who were waiting to see their doctor. Their 
participation rate was also high (93%), and 43% of 
patients had at least 2 risk factors. If performed contin-
uously or repeated regularly, such an approach might 
provide more complete and up-to-date information on 
a patient’s risk status in the EMR, improving the identi-
ﬁ cation of high-risk patients for screening purposes.
Greaves et al27 showed that identifying patients 
with type 2 diabetes and IFG using data stored in fam-
ily practice databases was feasible (NNS = 21-38 for 
type 2 diabetes), but instead of using an opportunistic 
approach, they invited high-risk patients (those aged 
>50 years and with a body mass index ≥27 kg/m2) 
to screening clinics run by trained practice nurses. 
The response rate was 61%. Nevertheless, the simple 
screening system they describe—like ours—would 
promote efﬁ cient use of scarce primary health care 
resources, especially when set up as part of a broader 
screening program to reduce cardiovascular disease.
In a cross-sectional study in a local family prac-
tice, Lawrence et al21 showed that screening of invited 
patients whose sole risk factor for diabetes is age older 
than 45 years has a low yield. In this group, they found 
a diabetes prevalence of just 0.2%. Among individuals 
with 1 or more other risk factors, the ﬁ gure increased 
to 2.8%. Both prevalences are comparable to ours.
Recently, a population-based screening program for 
type 2 diabetes was performed in The Netherlands.12 
Although the increase in diabetes prevalence achieved 
with the program (from 6.1% to 7.0% among people 
aged 50 to 70 years) was comparable to ours, the 
response to an invitation to glucose testing was 31% 
and the yield was only 1%. The authors concluded that 
opportunistic screening might be more appropriate.
Primary care practices often have large patient pop-
ulations, underscoring the need for a targeted approach 
to screening. In our family practices, more than two-
thirds of middle-aged and older study patients eligible 
for screening were at high risk. But largely because of 
the stepwise protocol, the yield of our opportunistic 
targeted screening method was fair.
In a recently updated statement,28 the US Preven-
tive Services Task Force recommends screening for 
type 2 diabetes in asymptomatic adults with hyper-
tension. As part of an assessment of cardiovascular 
disease risk, clinicians should also screen for diabetes 
to adequately assess patients’ risk for this condition 
as well.28 With ever greater integration of diabetes 
screening into cardiovascular risk management, oppor-
tunistic screening for type 2 diabetes in primary care 
could target middle-aged and older adults with obesity. 
With this approach, the number of high-risk patients to 
be screened would be considerably reduced. A similar 
approach was found to be cost-effective.29
With an opportunistic targeted screening program 
like ours, diabetes screening in primary care can be 
performed systematically and continuously, with prob-
ably few drawbacks for both patients and health care 
workers, and with efﬁ cient use of resources. Further 
research is needed to estimate its cost-effectiveness 
and limitations. Also, sensitivity and speciﬁ city of our 
stepwise approach need to be studied.
In conclusion, the yield of opportunistic targeted 
screening in our study was fair, and obesity alone 
was the best predictor of undiagnosed diabetes. Our 
data conﬁ rm a low yield when low-risk individuals 
are screened. As diabetes screening is increasingly 
integrated into cardiovascular risk management, oppor-
tunistic screening for type 2 diabetes in primary care 
could target middle-aged and older adults with obesity.
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/7/5/422.
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